What is OS Therapies's grants receivable?

OS Therapies (OSTX) reported grants receivable of $50K in Q2 2025.

What does grants receivable mean?

This represents the amount of funding awarded to the company through research or government grants that has been earned but not yet collected. It serves as a key indicator of non-dilutive capital inflows for clinical-stage companies. Tracking this helps investors gauge the company's success in securing external funding for its research and development pipeline.

OS Therapies OSTX Grants receivable

Grants receivable at other companies

Blink Charging Co.BLNK

$758K—

American Battery Technology CompanyABAT

$200K0.0%

Immix Biopharma, Inc.IMMX

$6.2M+265%

OS TherapiesOSTX

$50K—

ATN InternationalATNI

$37.46M—

Eos Energy Enterprises, Inc.EOSE

$10.34M+475%

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+66.4%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:GrantsReceivable.

The official record: OS Therapies’s 10-Q, filed November 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's grants receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's grants receivable?: OS Therapies (OSTX) reported grants receivable of $50K in Q2 2025.
What does grants receivable mean?: This represents the amount of funding awarded to the company through research or government grants that has been earned but not yet collected. It serves as a key indicator of non-dilutive capital inflows for clinical-stage companies. Tracking this helps investors gauge the company's success in securing external funding for its research and development pipeline.